BriaCell Therapeutics announced a clinical trial collaboration and supply agreement with Incyte. Under the terms of the agreement, BriaCell will evaluate combinations of novel therapeutics for the treatment of patients with advanced breast cancer. Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA0012, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with BriaCell’s lead candidate, Bria-IMT, in advanced breast cancer patients.
https://thefly.com/landingPageNews.php?id=2887629
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.